News and Press Releases
Ardena appoints Jeremie Trochu as Chief Executive Officer
3 June 2024 -- Ghent, Belgium -- Ardena today announces the retirement of Harry Christiaens PhD, and the subsequent appointment of Jeremie Trochu as chief executive officer. Jeremie is a...
Category: BioManufacturing, Biotechnology, Logistics, Manufacturing and Packing, Pharmaceutical
Posted: June 3, 2024
Johnson & Johnson submits application to the European Medicines Agency seeking approval of subcutaneous formulation of RYBREVANT▼ (amivantamab) for the treatment of patients with EGFR-mutated non-small cell lung cancer
Submission is supported by data from the phase 3 PALOMA-3 study featured at the American Society of Clinical Oncology (ASCO) Annual Meeting New formulation showed non-inferiority to intravenous administration in...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: May 31, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
RYBREVANT▼ (amivantamab) plus lazertinib shows longer progression-free survival versus osimertinib in the first-line treatment of patients with high-risk EGFR-mutated non-small cell lung cancer
Investigational chemotherapy-free regimen of amivantamab plus lazertinib addresses a significant unmet need as most patients with EGFR-mutated NSCLC have high-risk disease Landmark phase 3 MARIPOSA data featured in an oral...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: May 31, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Lykos Therapeutics Appoints Finance Veteran Scott Giacobello to the Board of Directors
30 May 2024 -- California, US -- Lykos Therapeutics, a company dedicated to transforming mental healthcare, announced the appointment of finance veteran Scott Giacobello to the company's Board of Directors, effective immediately. A...
Category: Biotechnology, Clinical Trials, Other
Posted: May 30, 2024
Biogen Receives European Commission Approval for QALSODY (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS
SOD1-ALS is a devastating, uniformly fatal and ultra-rare genetic form of ALS estimated to affect less than 1,000 people in Europe QALSODY is Biogen’s third rare disease therapy to be...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: May 30, 2024
Asymchem welcomes Franck Mevellec as senior director of Business Development
29 May 2024 -- Paris, France -- Asymchem, a leading global CDMO, is excited to announce the appointment of Franck Mevellec as senior director of business development. Franck brings over...
Category: BioManufacturing, Drug Discovery, Pharmaceutical
Posted: May 29, 2024
Asymchem Laboratories (Tianjin) Co., Ltd No. 6 Dongting 3rd Avenue, TEDA Tianjin, 300457, P.R. China
Mission Therapeutics commences landmark trial of MTX325, a potential disease-modifying treatment for Parkinson’s Disease
Builds on preclinical proof-of-concept that MTX325 protects dopamine-producing brain cells by enhancing mitophagy – the process cells use to remove dysfunctional mitochondria 21 March 2024 -- Cambridge, UK -- Mission...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: May 21, 2024
Moneta (Building 280), Babraham Research Campus, Cambridge, CB22 3AT, United Kingdom
Greenphire Named 2024 “Best Overall Patient Engagement Service” by MedTech Breakthrough Awards
16 May 2024 -- Pennsylvania, US -- Greenphire, a leading innovator in software solutions for improving clinical research site performance and participant satisfaction, has received a 2024 MedTech Breakthrough Award for...
Category: Clinical Trials, Logistics
Posted: May 16, 2024
Allyx Therapeutics Announces Positive Phase 1b Multiple Ascending Dose Data and Advances ALX-001 to Patients
Safety of ALX-001 reinforced by new data presented at AD/PD 2024 Conference in Lisbon, Portugal Two oral doses selected for further study in Alzheimer’s and Parkinson’s disease patients. 11 March 2024...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: May 11, 2024
Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness Within 24 Weeks and Initial Hearing Improvements in a Second Child at Six Weeks
Preliminary data detailed in an ASGCT oral presentation include results for one of the youngest children in the world to receive a gene therapy for genetic deafness Ongoing phase 1/2...
Category: Biotechnology, Clinical Trials
Posted: May 8, 2024
The Charter Building, Vine Street, Uxbridge, Middlesex, United Kingdom, UB8 1JG
Signant Health extends eCOA leadership position through operational innovations that reduce timelines by at least one-third
8 May 2024 -- Pennsylvania, US -- Signant Health, the leader in evidence generation for modern clinical trials, announced today that it has substantially reduced implementation timelines for its flagship...
Category: Clinical Trials, Other
Posted: May 8, 2024
Phesi launches predictive Patient Burden Score to improve trial efficiency, patient experience and investigator site performance
Latest real-world metric in Phesi’s AI-driven Trial Accelerator quantifies patient burden to unlock a patient-centric approach to trial design and implementation 7 May 2024 -- Boston, US -- Phesi, a...
Category: Clinical Trials
Posted: May 7, 2024
Kindeva Drug Delivery Invests in Second Manufacturing Line for Greener Inhalers at UK Manufacturing Site
6 May 2024 -- Minnesota, US, and Missouri, US -- Kindeva Drug Delivery, a global leader in drug-device combination products, today announced its investment in a second manufacturing line for...
Category: Drug Delivery, Manufacturing and Packing
Posted: May 6, 2024
TAR-210 results show 90% recurrence-free survival and 90% complete response in patients with high-risk and intermediate-risk non-muscle-invasive bladder cancer, respectively
Updated results reinforce the potential of TAR-210 to transform treatment of non-muscle-invasive bladder cancer with fibroblast growth factor receptor (FGFR) alterations 5 May 2024 -- Beerse, Belgium -- Janssen-Cilag International,...
Category: Clinical Trials, Drug Discovery
Posted: May 5, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Bespak and Medicines Evaluation Unit collaborate to accelerate clinical trials on climate-friendly inhalers
Relationship will provide pharmaceutical industry with fast route to clinical evaluation of low GWP pMDIs 3 May 2024 -- Holmes Chapel and Manchester, UK -- Bespak, a leading contract development...
Category: Clinical Trials, Drug Delivery
Posted: May 3, 2024
